Printer Friendly

QUIDEL FILES FOR FDA MARKETING CLEARANCE FOR NEW ONE-STEP PREGNANCY TEST

 QUIDEL FILES FOR FDA MARKETING CLEARANCE
 FOR NEW ONE-STEP PREGNANCY TEST
 SAN DIEGO, Oct. 13 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today said it has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance to market its new Conceive(TM) One-Step Pregnancy Test. This newest Conceive product is a rapid, one-step, one-minute test that allows women to detect pregnancy from three drops of urine as early as the first day of a missed period. All components necessary to complete the analysis, including the internal procedural control feature, are built into the test.
 The Conceive pregnancy test will be marketed as the companion product to the Conceive ovulation prediction test, which received FDA clearance earlier this year and is being distributed throughout the world. The Conceive pregnancy test will compete worldwide in a consumer market segment estimated at more than $215 million per year. Consumer market pregnancy testing is today considered the largest consumer fertility diagnostic market in the United States.
 The Conceive pregnancy test is designed in the same user-friendly device as the Conceive ovulation test and incorporates QUIDEL's newly developed and novel "Visual Label" technology. This one-step technology forms dye complexes to generate multicolor test results which increases the ease of interpretation by the end user. QUIDEL has applied for a patent for this new one-step technology.
 "We are very pleased with QUIDEL's strengthened proprietary technology position for developing and marketing a line of rapid, one-step diagnostic tests," said Scott L. Glenn, chairman and chief executive officer at QUIDEL. "The Conceive pregnancy test is second in this new line of rapid and accurate one-step tests under development by QUIDEL that offer superior ease-of-use. The Conceive pregnancy test will complement the Conceive ovulation prediction test and fit strategically into the ongoing national advertising and promotional campaign."
 QUIDEL Corp. develops, manufactures and markets rapid, immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 10/13/92
 /CONTACT: Mark Francois, manager, investor relations, of QUIDEL, 619-552-7931; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for QUIDEL/
 (QDEL) CO: QUIDEL Corp. ST: California IN: MTC SU: PDT


KJ-JB -- SD006 -- 9107 10/13/92 08:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:390
Previous Article:HOLLAND AMERICA LINE-WESTOURS INC. MARKS FIFTH CONSECUTIVE RECORD SEASON IN ALASKA FOR 1992
Next Article:IRVINE SENSORS CORP. ANNOUNCES CONTRACT FROM GRUMMAN CORP.
Topics:


Related Articles
QUIDEL'S NEW ONE-STEP CONCEIVE(TM) OVULATION TEST CLEARS FDA
QUIDEL FILES FOR FDA MARKETING CLEARANCE FOR RAPID FECAL OCCULT BLOOD TEST
QUIDEL OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
QUIDEL SEEKS FDA MARKETING CLEARANCE FOR ONE-STEP STREP TEST
QUIDEL UPDATES FDA SAFEPLAN(TM) STATUS
QUIDEL AND BECTON DICKINSON SIGN NEW AGREEMENT - QUIDEL ACQUIRES RIGHTS TO CONSUMER FERTILITY PRODUCTS
QUIDEL RECEIVES FDA CLEARANCE FOR DIP AND READ PREGNANCY TEST
QUIDEL RECEIVES FDA CLEARANCE FOR RAPID QUICKVUE(R) CHLAMYDIA TEST - TEST OFFERS SUPERIOR PERFORMANCE ADVANTAGES
QUIDEL RECEIVES FDA CLEARANCE FOR ONE-STEP QUICKVUE(R) ALLERGEN SCREEN
QUIDEL RECEIVES FDA CLEARANCE TO MARKET THE FIRST ONE-STEP, WHOLE BLOOD, RAPID H. PYLORI TEST

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters